<DOC>
	<DOCNO>NCT02495181</DOCNO>
	<brief_summary>The purpose study compare efficacy safety intravitreal Aflibercept monotherapy efficacy safety combine treatment Aflibercept plus standard photodynamic therapy ( PDT ) Verteporfin age-related macular degeneration ( AMD ) patient polypoidal choroidal vasculopathy ( PCV ) .</brief_summary>
	<brief_title>Randomized , Double-masked , Sham-controlled Phase 4 Study , Efficacy , Safety , Tolerability Intravitreal Aflibercept Monotherapy Compared Aflibercept With Adjunctive Photodynamic Therapy Patients With Polypoidal Choroidal Vasculopathy</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Either gender Age ≥ 50 . Naïve PCV patient . Confirmed diagnosis symptomatic macular PCV study eye . Greatest linear dimension lesion &lt; 5400 mm , assess ICG angiography . BCVA study entry 25 80 letter ( Snellen Equivalent 20/320 20/25 ) . Lesion size study eye study entry : Presence PCV assess Central Reading Centre base ICG active polyp without abnormal vascular network . Women must use effective contraception , postmenopausal least month prior trial entry , surgically sterile . Ability provide write informed consent . Ability return study visit . Active inflammation infection study eye . Uncontrolled intraocular pressure study eye . Ocular condition study eye may impact vision confound study outcome ( e.g . vitreomacular traction , epirretinal membrane BCVA impact , ocular inflammation , retinal vascular disease like diabetic retinopathy diabetic macular edema ) . Presence centromacular scarring atrophy indicate irreversible BCVA loss . Prior treatment study eye antiVEGF therapy systemic use antiVEGF product within 3 month prior study entry . Previous vitrectomy , macular laser treatment , PDT , intraocular steroid study eye .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>